Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTP42:KVA4 Phase I SAD/MAD in Healthy Volunteers
NCT04919863Phase 1Completed
- Sponsor
- ATXA Therapeutics
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing NTP42:KVA4 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single and repeated doses, Pharmacokinetics of single and repeated doses at 48 hours and 1 more. Started May 2021; status: completed.
02
Drugs
NTP42
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04919863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919863.